Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Zenas BioPharma, Inc. (ZBIO) is reported to have 1,000,000 common shares beneficially owned by Xencor, Inc., equal to 1.5% of the class. Xencor reported sole voting and dispositive power over 1,000,000 shares, with shared voting and dispositive power of zero. The percentage calculation uses 65,176,723 Zenas common shares outstanding as of July 31, 2026; the reported ownership is 5% or less.
Key Figures
Beneficially owned shares:1,000,000 sharesPercent of class:1.5%Issuer shares outstanding:65,176,723 shares
3 metrics
Beneficially owned shares1,000,000 sharesReported by Xencor, Inc.
Percent of class1.5%Based on shares outstanding as of July 31, 2026
Issuer shares outstanding65,176,723 sharesAs of July 31, 2026
Key Terms
Amount beneficially owned, Sole power to vote or to direct the vote, Sole power to dispose or to direct the disposition of
3 terms
Amount beneficially ownedregulatory
"Amount beneficially owned: 1,000,000"
Sole power to vote or to direct the voteregulatory
"Sole power to vote or to direct the vote: 1,000,000"
Sole power to dispose or to direct the disposition ofregulatory
"Sole power to dispose or to direct the disposition of: 1,000,000"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ZBIO shares did Xencor report owning?
Xencor, Inc. reported beneficial ownership of 1,000,000 Zenas BioPharma common shares, representing 1.5% of the class. It reported sole voting and dispositive power over those shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Zenas BioPharma, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
98937L105
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
98937L105
1
Names of Reporting Persons
Xencor, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,000,000.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,000,000.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,000,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.5 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Zenas BioPharma, Inc.
(b)
Address of issuer's principal executive offices:
852 Winter Street, Suite 250, Waltham, Massachusetts, 02451
Item 2.
(a)
Name of person filing:
Xencor, Inc. (the "Reporting Person")
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of the Reporting Person is:
465 N. Halstead St., Suite 200
Pasadena, California 91107
(c)
Citizenship:
The Reporting Person is a corporation organized under the laws of the State of Delaware.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
98937L105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1,000,000
(b)
Percent of class:
1.5%
This percentage is calculated based upon 65,176,723 shares of the Issuer's Common Stock outstanding as of July 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
1,000,000
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
1,000,000
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Xencor, Inc.
Signature:
/s/ Celia Eckert
Name/Title:
Celia Eckert, General Counsel & Corporate Secretary
